Janssen has launched guselkumab (Tremfya) for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. Janssen says that guselkumab is the first biologic to “selectively target interleukin-23, a key protein that initiates a specific immune inflammatory response”.


Paracetamol, pregnancy and language

Exposure to paracetamol during pregnancy seems to increase the risk of language delay in girls, but not boys

Warfarin may cut cancer risk

Research suggests warfarin may have anti-cancer potential. Could this have implications for anticoagulation patients?